当前位置： SCI文献检索 > PROSTATE CANCER AND PROSTATIC DISEASES期刊下所有文献 > Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up.

Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up.

Abstract：

:The Gyrus system uses bipolar electrocautery with saline irrigation to vaporize prostatic tissue and is compared to transurethral resection of the prostate (TURP) in a randomized prospective study with 1 y follow-up. Outcomes measured were fluid absorption, blood loss, period of catheterization, hospital stay, symptom scores, quality of life, flow rates, and post-void residual volumes at 3, 6, and 12 months. All measured parameters were similar, although re-catheterization rates were higher (30% vs 5%) in the Gyrus group. Clot evacuation rates were higher in the TURP group (19% vs 0%). The Gyrus device is safe and produces results that are similar to TURP at 1 y.

journal_name

Prostate Cancer Prostatic Dis

journal_title

Prostate cancer and prostatic diseases

authors

Dunsmuir WD,McFarlane JP,Tan A,Dowling C,Downie J,Kourambas J,Donnellan S,Redgrave N,Fletcher R,Frydenberg M,Love C

doi

10.1038/sj.pcan.4500631

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

182-6

issue

2

eissn

1365-7852

issn

1476-5608

pii

4500631

journal_volume

6

pub_type

临床试验,杂志文章,随机对照试验

相关文献

PROSTATE CANCER AND PROSTATIC DISEASES文献大全
  • Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferation.

    abstract：:We have identified a novel function for a member of the transient receptor potential (TRP) protein super-family, TRPM2, in prostate cancer cell proliferation. TRPM2 encodes a non-selective cation-permeable ion channel. We found that selectively knocking down TRPM2 with the small interfering RNA technique inhibited the...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2009.55

    authors： Zeng X,Sikka SC,Huang L,Sun C,Xu C,Jia D,Abdel-Mageed AB,Pottle JE,Taylor JT,Li M

    更新日期：2010-06-01 00:00:00

  • The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.

    abstract：BACKGROUND:Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there i...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2017.29

    authors： Tosco L,Laenen A,Briganti A,Gontero P,Karnes RJ,Albersen M,Bastian PJ,Chlosta P,Claessens F,Chun FK,Everaerts W,Gratzke C,Graefen M,Kneitz B,Marchioro G,Salas RS,Tombal B,Van den Broeck T,Moris L,Battaglia A,van d

    更新日期：2017-12-01 00:00:00

  • Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.

    abstract：:Antiandrogen therapy is an important modality in the treatment of prostate cancer. Recent research into the role of angiogenesis in tumour growth and metastasis has uncovered links between antiandrogen therapy, radiation therapy and angiogenesis, which have exciting implications for the treatment of prostate cancer. A...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500779

    authors： Woodward WA,Wachsberger P,Burd R,Dicker AP

    更新日期：2005-01-01 00:00:00

  • A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.

    abstract：BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章

    doi：10.1038/pcan.2015.55

    authors： van Velthoven R,Aoun F,Marcelis Q,Albisinni S,Zanaty M,Lemort M,Peltier A,Limani K

    更新日期：2016-03-01 00:00:00

  • High-intensity interval training produces a significant improvement in fitness in less than 31 days before surgery for urological cancer: a randomised control trial.

    abstract：OBJECTIVES:To assess the efficacy of high-intensity interval training (HIIT) for improving cardiorespiratory fitness (CRF) in patients awaiting resection for urological malignancy within four weeks. SUBJECTS/PATIENTS AND METHODS:A randomised control trial of consecutive patients aged (>65 years) scheduled for major ur...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0219-1

    authors： Blackwell JEM,Doleman B,Boereboom CL,Morton A,Williams S,Atherton P,Smith K,Williams JP,Phillips BE,Lund JN

    更新日期：2020-12-01 00:00:00

  • The role of external radiotherapy in patients treated with permanent prostate brachytherapy.

    abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500552

    authors： Potters L,Fearn P,Kattan M

    更新日期：2002-01-01 00:00:00

  • The potential role of bisphosphonates in prostate cancer.

    abstract：:Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphon...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500607

    authors： Oades GM,Coxon J,Colston KW

    更新日期：2002-01-01 00:00:00

  • Impact of age on exposure to oral antiandrogen therapies in clinical practice.

    abstract：BACKGROUND:Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AN...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-018-0096-z

    authors： Crombag MBS,van Nuland M,Bergman AM,Rosing H,Schellens JHM,Huitema ADR,Beijnen JH

    更新日期：2019-03-01 00:00:00

  • A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo.

    abstract：:Functional expression of voltage-gated sodium channel alpha-subunits (VGSCalphas), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCalpha expression in CaP...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500796

    authors： Diss JK,Stewart D,Pani F,Foster CS,Walker MM,Patel A,Djamgoz MB

    更新日期：2005-01-01 00:00:00

  • The microbiome in prostate inflammation and prostate cancer.

    abstract：BACKGROUND:The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-018-0041-1

    authors： Porter CM,Shrestha E,Peiffer LB,Sfanos KS

    更新日期：2018-09-01 00:00:00

  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

    abstract：BACKGROUND:In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (RT). METHODS:This was a phase 2 single-arm prospective open...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.59

    authors： Armstrong AJ,Halabi S,Healy P,Lee WR,Koontz BF,Moul JW,Mundy K,Creel P,Wood S,Davis K,Carducci MA,Stein M,Hobbs C,Reimer B,Nguyen M,Anand M,Bratt L,Kim S,Tran PT,George DJ,Department of Defense Prostate Cancer Cli

    更新日期：2016-03-01 00:00:00

  • Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.

    abstract：:The purpose of this study was to identify the early predictor of survival for prostate cancer patients with bone metastasis. We reviewed 87 prostate cancer patients with bone metastasis who had received primary androgen deprivation therapy (PADT) at our institution. The medical records of the patients were examined wi...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.14

    authors： Sasaki T,Onishi T,Hoshina A

    更新日期：2011-09-01 00:00:00

  • Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications.

    abstract：:As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500210

    authors： Feneley MR,Green JS,Young MP,Bose P,Kirby RS,Peeling WB,Parkinson MC

    更新日期：1997-12-01 00:00:00

  • Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.

    abstract：:The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4501001

    authors： Stoss O,Werther M,Zielinski D,Middel P,Jost N,Rüschoff J,Henkel T,Albers P

    更新日期：2008-01-01 00:00:00

  • Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.

    abstract：:Side effects accompanying androgen deprivation therapy (ADT), including sarcopenia, loss of bone mass and reduction in muscle strength, can compromise physical function, particularly in older patients. Exercise, specifically resistance training, may be an effective and cost-efficient strategy to limit or even reverse ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500975

    authors： Galvão DA,Taaffe DR,Spry N,Newton RU

    更新日期：2007-01-01 00:00:00

  • Associations among statins, preventive care, and prostate cancer mortality.

    abstract：BACKGROUND:Increasing evidence indicates an association between statins and reduced prostate cancer-specific mortality (PCSM). However, significant bias may exist in these studies. One particularly challenging bias to assess is the healthy user effect, which may be quantified by screening patterns. We aimed to evaluate...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0207-5

    authors： Kumar A,Riviere P,Luterstein E,Nalawade V,Vitzthum L,Sarkar RR,Bryant AK,Einck JP,Mundt AJ,Murphy JD,Rose BS

    更新日期：2020-09-01 00:00:00

  • High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.

    abstract：:The role of neoadjuvant androgen deprivation (NAD) in high-risk prostate cancer patients receiving high-dose radiotherapy (RT) remains unstudied. To evaluate the effect of a course of NAD, we reviewed the experiences of three institutions treating these patients with combined RT and high-dose rate brachytherapy (HDR)....

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.pcan.4500882

    authors： Vargas C,Martínez A,Galalae R,Demanes J,Harsolia A,Schour L,Nuernberg N,Gonzalez J

    更新日期：2006-01-01 00:00:00

  • The very-high-risk prostate cancer: a contemporary update.

    abstract：BACKGROUND:Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment altern...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2016.40

    authors： Mano R,Eastham J,Yossepowitch O

    更新日期：2016-12-01 00:00:00

  • A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

    abstract：BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/pcan.2011.49

    authors： Ward JE,Karrison T,Chatta G,Hussain M,Shevrin D,Szmulewitz RZ,O'Donnell PH,Stadler WM,Posadas EM

    更新日期：2012-03-01 00:00:00

  • Adjuvant and salvage treatment after radical prostatectomy: current practice in the UK.

    abstract：OBJECTIVE:To survey UK urologists and radiation oncologists in the evaluation and treatment of localised prostate cancer in the adjuvant and salvage setting. METHODS:Postal questionnaires were mailed to 292 urologists and 98 radiation oncologists in the UK. RESULTS:In all, 188 (48%) questionnaires were returned. In t...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500816

    authors： Lee LW,Clarke NW,Ramani VA,Cowan RA,Wylie JP,Logue JP

    更新日期：2005-01-01 00:00:00

  • High level of dioxin-TEQ in tissue is associated with Agent Orange exposure but not with biochemical recurrence after radical prostatectomy.

    abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2013.33

    authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

    更新日期：2013-12-01 00:00:00

  • GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.

    abstract：BACKGROUND:Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS:Retrospective analysis was conducted for 94 patients diagnosed with a Gleas...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0202-x

    authors： Meziou S,Ringuette Goulet C,Hovington H,Lefebvre V,Lavallée É,Bergeron M,Brisson H,Champagne A,Neveu B,Lacombe D,Beauregard JM,Buteau FA,Riopel J,Pouliot F

    更新日期：2020-09-01 00:00:00

  • Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.

    abstract：BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2015.48

    authors： Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

    更新日期：2016-03-01 00:00:00

  • Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

    abstract：BACKGROUND:To assess the added value of biopsy factors, like maximum cancer length in a core (MCL), cumulative cancer length (CCL), cumulative length of positive cores (CLPC), percentage of cancer involvement in positive cores (CIPC) and the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria i...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.26

    authors： Russo GI,Castelli T,Favilla V,Reale G,Urzì D,Privitera S,Fragalà E,Cimino S,Morgia G

    更新日期：2015-12-01 00:00:00

  • Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells.

    abstract：:Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopr...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2010.26

    authors： Choi HY,Lim JE,Hong JH

    更新日期：2010-12-01 00:00:00

  • Androgen receptor antigen density and S-phase fraction in prostate cancer: a pilot study.

    abstract：PURPOSE:To determine whether quantitative flow cytometric androgen receptor density expression (MFC ratio) in prostate cancer was associated with S-phase fraction. METHODS:Flow cytometry was performed to determine DNA aneuploidy, S-phase fraction, percentage of androgen receptor (AR)-positive cells, and MFC ratio in p...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500672

    authors： Abdel-Wahab M,Krishan A,Milikowski C,Wahab AA,Walker G,Markoe A

    更新日期：2003-01-01 00:00:00

  • Exposure to direct-to-consumer advertising is associated with overestimation of benefits regarding ultrahypofractionated radiation therapy for prostate cancer.

    abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0234-2

    authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

    更新日期：2020-12-01 00:00:00

  • Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.

    abstract：BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-019-0197-3

    authors： Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

    更新日期：2020-09-01 00:00:00

  • The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.

    abstract：INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500889

    authors： Kastner C,Armitage J,Kimble A,Rawal J,Carter PG,Venn S

    更新日期：2006-01-01 00:00:00

  • Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer.

    abstract：BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-019-0136-3

    authors： Matsumoto K,Akita H,Narita K,Hashiguchi A,Takamatsu K,Takeda T,Kosaka T,Mizuno R,Kikuchi E,Oya M,Jinzaki M

    更新日期：2019-12-01 00:00:00